07:32 AM EDT, 09/18/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of AstraZeneca (AZN.L, AZN.ST) unit Alexion Europe's klygefa drug for generalized myasthenia gravis, a rare and chronic autoimmune disease. Klygefa is indicated as an add-on to standard therapy for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive, according to a Friday release. The committee's endorsement is based on study results showing klygefa's efficacy in reducing disease severity, as well as improving function and quality of life. The drug is pending marketing approval from the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.